FDA agrees ENABLE-2 Phase III trial design for Enliven’s relcobatinib

Phase 3relcobatinibPositive

AI Analysis

Summary

Enliven Therapeutics reached an FDA agreement on the final protocol design for the ENABLE-2 Phase III pivotal trial evaluating relcobatinib in adults with chronic myeloid leukemia.

Clinical Trial Data

Phase

Phase III

Outcome Details

FDA agreed on final ENABLE-2 Phase III trial protocol design

Importance:6/10

Sentiment:

0.60

FDAPhase IIICMLprotocol agreement

Related Companies

$TRAX $ARNA

Read the original article

Published by Clinical Trials Arena on October 7, 2026 9:43 AM

Read Original